等待开盘 11-16 09:30:00 美东时间
-0.160
-4.30%
Azora Therapeutics, a biopharmaceutical company, began trading on Nasdaq as "AZR" and appointed a new executive team and Board of Directors. The company is advancing its AT177 program, targeting an IND submission and Phase 1a trial in the first half of 2027. AT177 is an oral, colon-targeted AhR agonist for ulcerative colitis. The company reported a net loss of $64.6 million for Q3 2026 and had $22 million in cash as of September 30, 2026.
11-12 21:05
Verrica Pharmaceuticals Inc. announced that its CEO, Jayson Rieger, will present at the Jefferies Global Healthcare Conference in London on November 19, 2026. The event will be webcast live and available for replay on the company's website. Verrica specializes in developing treatments for dermatological diseases, including skin cancers, with FDA-approved YCANTH® for molluscum contagiosum and VP-315 for non-melanoma skin cancers.
11-10 13:00
Azora Therapeutics, a biopharma company, has formed a five-member board of directors with extensive drug development and governance expertise. The board includes Matt Davidson, CEO and co-founder; Wendy Young, a seasoned medicinal chemist; Aida Habtezion, a gastroenterology and immunology expert; Thomas Soloway, CEO of T-knife Therapeutics; and Paul Hastings, CEO of Nkarta. The company is advancing AT177, an oral aryl hydrocarbon receptor agonist...
11-05 12:00
Verrica shares are trading higher after the company unlocked an additional $15 million under its credit facility, increasing available non-dilutive funding to $27.5 million to support YCANTH growth and its Phase 3 common warts program.
10-23 00:37
Verrica Pharmaceuticals Inc. has achieved predefined revenue, growth, and operational milestones, unlocking an additional $15 million under its credit facility, making the full $27.5 million available. This capital will support the continued growth of YCANTH® and advance its global Phase 3 common warts program, with the first topline data expected in Q1’27. The facility’s terms include interest at SOFR + 8.00% and maturity in 2030, with no schedu...
10-22 12:00
Verrica Pharmaceuticals (NASDAQ:VRCA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call...
10-14 17:37
Verrica Pharmaceuticals announced it will present new Phase 3 trial analyses of YCANTH® (VP-102) and an encore presentation of VP-315 data at upcoming conferences. YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, with 60.1% clearance by Day 84 vs. 19.9% for vehicle. VP-315 showed potential abscopal effects in basal cell carcinoma. The posters will be presented at the Fall Clinical Dermatology ...
09-30 12:00
Verrica Pharmaceuticals Inc. announced that its CEO, Jayson Rieger, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, in New York. The event will be live webcast and available for replay on the company's website. Verrica specializes in developing treatments for dermatological diseases, including skin cancers, with its product YCANTH® (VP-102) approved for molluscum contagiosum and under developmen...
09-08 12:00
Verrica Pharmaceuticals announced the completion of enrollment in the first pivotal Phase 3 trial (COVE-2) for YCANTH® (VP-102) in treating common warts. An interim analysis confirmed no additional patients are needed for full enrollment. The second trial (COVE-3) has exceeded 50% of its target enrollment and is expected to provide top-line data by mid-2027. YCANTH has the potential to become the first FDA-approved prescription drug for common wa...
08-27 12:00
Verrica Pharmaceuticals (($VRCA)) has held its Q2 earnings call. Read on for th...
08-22 08:26